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Abstract
Recent findings linked gastrointestinal disorders characterized by abdominal pain to gut microbiota composition. The present work
aimed to evaluate the power of gut microbiota as a visceral pain modulator and, consequently, the relevance of its manipulation as a
therapeutic option in reversing postinflammatory visceral pain persistence. Colitis was induced in mice by intrarectally injecting 2,4-
dinitrobenzenesulfonic acid (DNBS). The effect of faecal microbiota transplantation from viscerally hypersensitive DNBS-treated and
naive donors was evaluated in control rats after an antibiotic-mediated microbiota depletion. Faecal microbiota transplantation from
DNBSdonors induced a long-lasting visceral hypersensitivity in control rats. Pain threshold trend correlatedwithmajormodifications
in the composition of gut microbiota and short chain fatty acids. By contrast, no significant alterations of colon histology,
permeability, and monoamines levels were detected. Finally, by manipulating the gut microbiota of DNBS-treated animals, a
counteraction of persistent visceral pain was achieved. The present results provide novel insights into the relationship between
intestinal microbiota and visceral hypersensitivity, highlighting the therapeutic potential of microbiota-targeted interventions.
Keywords: Microbiota-gut-brain axis, Visceral pain, IBS, IBDs, Faecal microbiota transplantation
1. Introduction
Visceral pain management is a major clinical problem, given the lack
of effective and safe drugs.15 The development of a chronic visceral
hypersensitivity frequently occurs in patients with a history of
intestinal damage. Indeed 20% to 50% of patients affected by
inflammatory bowel diseases (IBDs) manifest a chronic abdominal
pain also in the remission phase of colitis. On the other hand, an
acute gut illness increases the risk of developing the irritable bowel
syndrome (IBS) by 7-fold.81 Several mechanisms have been
proposed to contribute to the initiation, exacerbation, and persis-
tence of visceral pain. Among them, there is dysbiosis of gut
microbiota.32,47,70 The most well-documented line of evidence
linking the loss of gastrointestinal microbial homeostasis to the
development of chronic visceral hypersensitivity comes from the
literature on postinfectious IBS.54 Consistently, the disturbance of
the gut microbiota in early life71 as in adulthood affects the local
immune response and enhances pain signalling in rodents.45,60,86
The brain, the gut microbiota, and the immune system show
reciprocal associations in health and disease.34 The brain, by the
autonomic nervous system and the hypothalamic–pituitary–adrenal
axis, influences intestinal functions and gut microbial composition.77
On the other hand, microbiota alterations can influence brain
structure and function either developmentally or in response to acute
perturbations, setting a regulatory loop between the gut and the
brain.26,65 Although alterations of the gut bacteria composition or
metabolism caused by intestinal inflammation have been correlated
to postinflammatory visceral pain persistence,30,33 a definitive
cause–effect relationship between dysbiosis and visceral pain
persistence as well as the potential of microbiota as pain generator
or pain perpetuator has not yet been determined. Microbiota
metabolites, namely, short-chain fatty acids (SCFAs), amino acid–
derived metabolites, and bile acids, can promote anti-inflammatory
and immunoregulatory effects in different cells within the gastroin-
testinal tract, thereby indirectly affecting visceral sensitivity.57,62 In
addition, these products can translocate across the epithelial barrier
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into the systemic circulation, thus modulating distant organs, such
as the brain and spinal cord, by activating or inhibiting specific
receptors therein.41,57 The aims of the present work were (1) to
evaluate the effect of faecal microbiota transplantation (FMT) from
viscerally hypersensitive donors in remission from colitis induced by
2,4-dinitrobezenesulfonic acid (DNBS) on controls visceral sensitiv-
ity, (2) to study the mechanisms by which the gut microbiota can
directly affect pain perception, and (3) to evaluate the therapeutic
efficacy of FMT on persistent postinflammatory visceral pain.
2. Methods
2.1. Animals
For all the experiments described below, 8-week-old male
Sprague–Dawley rats (Envigo, Varese, Italy), weighing approxi-
mately 220 to 250 g at the beginning of the experimental
procedure, were used. Animals were housed in CeSAL (Centro
Stabulazione Animali da Laboratorio, University of Florence) and
used at least 1 week after their arrival. Before starting the
treatments, 4 animals were housed per cage (size 26 3 41 cm).
After starting the experimental procedures, animals were in-
dividually housed to avoid the damage of the electrodes
implanted for electrophysiological measurements. Animals were
fed a standard laboratory diet and tapwater ad libitum and kept at
23˚C 6 1˚C with a 12 hours light or dark cycle, light at 7 AM. All
animal manipulations were performed according to the Directive
2010/63/EU of the European parliament and of the European
Union council (September 22, 2010) on the protection of animals
used for scientific purposes. The ethical policy of the University of
Florence complies with the Guide for the Care and Use of
Laboratory Animals of the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996; University of Florence
assurance number: A5278-01). Formal approval to conduct the
described experiments was obtained from the Animal Subjects
Review Board of the University of Florence. Experiments involving
animals have been reported according to ARRIVE guidelines.66
All efforts were made to minimize animal suffering and to reduce
the number of animals used.
2.2. Induction of colitis
Colitis was induced in accordance with the method described
previously by Antonioli et al.3 withminor changes. In brief, during a
short anaesthesia with isoflurane (2%), 30mg of DNBS in 0.25mL
of 50% ethanol was administered intrarectally through a poly-
ethylene PE-60 catheter inserted 8 cm proximal to the anus.
Control rats received 0.25 mL of saline solution.
2.3. Faecal microbiota transplantation study design
In the first experimental set, rats were randomized into the following
treatment groups: control (vehicle, no antibiotic treatment, no FMT; n
5 10), antibiotics (abx) 1 vehicle (antibiotic treatment followed by
vehicle administration; n5 10), abx1 FMTCTR (antibiotic treatment
followed by FMT from controls; n 5 10), and abx 1 FMTDNBS
(antibiotic treatment followed by FMT from DNBS treated animals; n
5 14). The animals were singly housed and underwent the following
antibiotic or antifungal regimen to prepare them to the FMT: Day 0 to
6 rats received adaily oral gavage of amphotericinB (1mg·kg21) and
metronidazole (100mg·kg21) whereas an antibiotic mix (ceftazidime
1g·L21, vancomycin 0.5 g·L21, and neomicin 1 g·L21) was added to
the autoclaved drinking water and changed every 2 days. On day 7,
24 hours after the interruption of the antibiotic treatment, the animals
underwent the FMT procedure. FMTwas daily performed on days 7
to 11 (set I) and on days 20 to 24 (set II). Behavioural tests were
performed at the end of the antibiotic treatment (before starting the
FMT), 24 hours and 7 days after each FMT set, and once a week
after the last treatment. Effects of the antibiotic or antifungal
treatments on the gut microbiota were evaluated by a culture-
based analysis for each treatment group. A portion of fresh faecal
pellets (50 mg) was dissolved in 1 mL of sterile saline by vigorous
vortexing, and the mean viable cell count was then determined by
plating 0.1 mL of appropriate dilutions (detection range, 2 3 102 to
16 3 108 CFU/g of faecal pellet) onto (1) MacConkey agar (Oxoid,
Cheshire, United Kingdom), selective for isolation of Gram-negative
enteric bacteria; (2) CNA-CV Agar (Becton, Dickinson and
Company, Franklin Lakes, NJ), selective for isolation of Gram-
positive cocci; and (3) Sabouraud glucose agar (Becton, Dickinson
and Company), selective for isolation of yeasts. Faecal material
collected from different controls (n5 3) or DNBS-treated animals (n
5 3) (between 14 and 21 days after the intrarectal injection of the
inflammatory agent) have been homogenized into one solution for
FMTCTR and FMTDNBS, respectively. Tube containing fecal pellets in
sterile saline solution were left on ice for 60 minutes and later
homogenized for 2 minutes on ice using a hand-held pellet pestle
device with sterile, reuseable pestles. When fully homogenized, the
suspended pellets were directly used for the FMT procedure. FMT
was performed through oral gavage with a faecal suspension (50
mg·mL21) in a final volume of 3 mL. The following analyses have
been performed on 3 to 6 samples per group collected from the
same animals used for the behavioural assessments.
In the second experimental set, rats were randomized into the
following treatment groups (n5 5): control (vehicle), DNBS1 vehicle
(intrarectal injection of DNBS 30 mg followed by vehicle administra-
tion), and DNBS 1 FMTCTR (intrarectal injection of DNBS 30 mg
followedbyFMT fromcontrols). Colitiswas induced in animals by the
intrarectal injection of DNBS (30mg in 0.25mLEtOH50%) on day 1.
A control group was intrarectally administered with saline solution.
DNBS-treated animals did not receive the antibiotic pretreatment
before the FMT because it has been reported in the literature that
antibiotics can influence the course of the colitis.43,52 Seven days
after DNBS injection, the animals were split into 2 groups,
respectively, receiving the vehicle or the naive control–derived faecal
microbiota suspensions (FMTCTR). Because the resident microbiota
represents an obstacle to the engraftment of the new microbiota,
FMT was performed for 5 consecutive days/week and the same
protocol was repeated for 4 weeks (I-IV set of FMT): on days 7 to 11
(set I), 14 to18 (set II), 21 to25 (set III), and28 to32 (set IV) afterDNBS
injection. Behavioural tests were conducted 7 days after DNBS
injection (before startingFMT), 3days after eachFMTset, andoncea
week after the last treatment. For the FMT, faecal material was
collected from different control naive animals (n 5 3) and
homogenized into one tube containing sterile saline solution. Tubes
were left on ice for 60minutesand later homogenized for 2minon ice
using a hand-held pellet pestle devicewith sterile, reuseable pestles.
When fully homogenized, the suspended pellets were directly used
for the FMT procedure. FMT was performed by oral gavage with a
faecal suspension (100 mg·mL21) in a final volume of 3 mL.
2.4. Assessment of visceral sensitivity by
visceromotor response
The visceromotor response (VMR) to colorectal balloon disten-
sion was used as a objective measure of visceral sensitivity in
animals. Two electromyographic electrodeswere sutured into the
external oblique abdominal muscle under deep anaesthesia and
exteriorised dorsally.22 Visceromotor response assessment was
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performed under light anaesthesia (isoflurane 2%) as previously
reported.75 A lubricated latex balloon (length: 4.5 cm), assembled
to an embolectomy catheter and connected to a syringe filledwith
water, was used to perform colorectal distension. The balloon
was inserted into the colon and positioned 6.5 cm from the anus
and was filled with increasing volumes of water (0.5, 1, 2, and 3
mL). The electrodes were relayed to a data acquisition system,
and the corresponding electromyographic signal consequent to
colorectal stimulation was recorded, amplified and filtered
(Animal Bio Amp; ADInstruments, Oxford, United Kingdom),
digitised (PowerLab 4/35; ADIinstruments), analysed, and
quantified using LabChart 8 (ADInstruments). To quantify the
magnitude of the VMR at each distension volume, the area under
the curve immediately before the distension (30 seconds) was
subtracted from the area under the curve during the balloon
distension (30 seconds) and responses were expressed as
percentage increase from the baseline. The time elapsed
between 2 consecutive distension was 5 minutes. Visceromotor
response measurements were performed in 5 animals per group.
2.5. Assessment of visceral sensitivity by abdominal
withdrawal reflex
The behavioural responses to colorectal distension (CRD) were
assessed in the animals by measuring the abdominal withdrawal
reflex (AWR), a semiquantitative score described previously in
conscious animals.19 In brief, rats were anesthetized with isoflurane,
and a lubricated latex balloon (length: 4.5 cm), attached to
polyethylene tubing, assembled to an embolectomy catheter, and
connected to a syringe filled with water, was inserted through the
anus into the rectum and descending colon of adult rats. The tubing
was taped to the tail to hold the balloon in place. Then rats were
allowed to recover from the anaesthesia for 30 minutes. AWR
measurement consisted of visual observation of animal responses to
graded CRD (0.5, 1, 2, and 3 mL) blinded observers who assigned
AWR scores: no behavioral response to colorectal distention (0);
immobile during colorectal distention and occasional head clinching
at stimulus onset (1); mild contraction of the abdominal muscles but
absence of abdomen lifting from the platform (2); observed strong
contraction of the abdominal muscles and lifting of the abdomen off
the platform (3); and arching of the body and lifting of the pelvic
structures and scrotum (4). The timeelapsedbetween2consecutive
distension was 5 minutes. AWR measurements were conducted in
10 to 14 animals per group.
2.6. Profiling of the gut microbiota
Fecal pellets (50 mg) and fecal suspensions (volume equivalent to
50 mg) were processed for the total DNA extraction using the
DNeasy PowerLyzer PowerSoil Kit (Qiagen, Hilden, Germany).
Next-generation sequencing of 16S ribosomal RNA amplicons
(V3-V4 regions) was performed using the IlluminaMiSeq platform,
according to the Illumina 16S Metagenomic Sequencing Library
Preparation protocol (Part # 15044223 Rev. B; URL: http://www.
illumina.com/content/dam/illumina-support/documents/docu-
mentation/chemistry_documentation/16s/16s-metagenomic-li-
brary-prep-guide-15044223-b.pdf), after a 2 3 300 bp paired-
end approach. Sequencing results were analyzed using the
QIIME 2 suite (Quantitative Insights Into Microbial Ecology).11 In
brief, after raw reads denoising (ie, error correction, removal of
chimeric and singleton sequences, and joining of denoised
paired-end reads), using DADA214 for each sample amplicon
sequence variants was inferred. Taxonomic classification of
dereplicated amplicon sequence variant was performed using a
Naive Bayes classifier trained on the SILVA 16S reference
database (release 132) (https://www.arb-silva.de/documenta-
tion/release-132/). Microbial diversity was estimated by evaluat-
ing alpha diversity (Shannon index) and beta diversity (Bray-
Curtis) metrics using specific tools implemented in the QIIME 2
pipeline. The analysis was not performed in a within-subject
manner.
The gut microbiota was characterized in a representative
number of animals, at different sampling points (day 18, 32, and
46), belonging to the following treatment groups: vehicle 1
vehicle (n 5 3), abx 1 vehicle (n 5 4), abx 1 FMTCTR (n 5 4),
and abx 1 FMTDNBS (n 5 4). The first and the last faecal
suspension used in the I and II set of either FMTCTR (n 5 4) or
FMTDNBS (n 5 4) were also analysed to determine the
composition of the transplanted microbiota.
2.7. Gas chromatography mass spectrometry analysis of
short-chain fatty acids
Methanol and tert-butyl methyl ether (Chromasolv grade), sodium
bicarbonate and hydrochloric acid (reagent grade), (2H3)Acetic,
(2H3)Propionic, (2H7)isobutyric and (2H9)isovaleric (used as internal
standards [ISTDs]), acetic acid, propionic acid, butyric acid,
isobutyric acid, valeric acid, and isovaleric acid (analytical standards
grade) were purchased fromSigma-Aldrich (Milan, Italy). MilliQwater
18 MW was obtained from the Millipore Simplicity system (Milan,
Italy). The analysis of SCFAs was performed by an Agilent gas
chromatographymass spectrometry systemcomposedwith a 5971
single quadrupole mass spectrometer, 5890 gas-chromatograph,
and 7673 autosampler.
The SCFAs in the fecal samples were analyzed as free acid
form using a SupelcoNukol column, with a 30 m length, 0.25 mm
internal diameter, and 0.25 mm of film thickness with the
temperatures program as follows: Initial temperature of 40˚C
was held for 1 minute, then it was increased to 150˚C at 30˚C/
minute, and finally increased to 220˚C at 20˚C/minute. A 1 mL
aliquot of the extracted sample was injected in splitless mode
(splitless time 1 minute) at 250˚C, whereas the transfer line
temperature was 280˚C. The carrier flow rate was maintained at 1
mL/minutes. The quantitative determination of SCFAs in each
sample was performed by the ratio between the area abundance
of the analytes with the area abundance of respective labeled
ISTD (isotopic dilution method). The value of this ratio was named
the peak area ratio, and it was used as abundance of each analyte
in the quantitative evaluation. The ionic signals of SCFAs and the
reference ISTDs used for the quantitation of each SCFAs were
reported in the supplementary information (available as supple-
mental digital content at http://links.lww.com/PAIN/B462). Fae-
cal samples were added to sodium bicarbonate 10 mM solution
(1:1w/v). Themixturewas sonicated 5minutes and centrifuged at
5000 rpm for 10minutes. The supernatants were frozen at220˚C
until analysis. The SCFAs were finally extracted as follows: An
aliquot of 100 mL of sample solution (corresponding to 0.1 mg of
stool sample) was added of 50 mL of ISTDs mixture, 1 mL of tert-
butyl methyl ether and 50 mL of 1.0 M HCl solution in 1.5 mL
centrifuge tube. Afterwards, each tube was shaken in a vortex
apparatus for 2minutes, centrifuged at 10,000 rpm for 5minutes,
and finally the solvent layer was transferred in autosampler vial
and analyzed by the gas chromatography mass spectrometry
method. Each sample was prepared and processed, by the
method described above in triplicate. The analysis has been
performed in 5 to 9 animals per group. Short-chain fatty acids
were analysed at each timepoint in the groups receiving the FMT
and at day 0, 18, and 46 in the control groups, abx1 vehicle, and
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vehicle 1 vehicle group. Further details are reported in the
supplementary information (available as supplemental digital
content at http://links.lww.com/PAIN/B462).
2.8. Histological evaluation of colonic damage
The evaluation of colon damage was performed both macro-
scopically and histologically, in accordance with the criteria
previously reported by Antonioli et al.3 The macroscopic criteria
were presence of adhesions between colon and other intra-
abdominal organs (0-2), consistency of colonic faecal material
(indirect marker of diarrhoea; 0-2), thickening of colonic wall
(millimeters), and presence and extension of hyperaemia and
macroscopic mucosal damage (0-5). A microscopic analysis was
performed on haematoxylin or eosin-stained sections of formalin-
fixed full-thickness samples obtained from the distal colon. The
microscopic damage was assessed in accordance with the
criteria reported previously by Antonioli et al.2 by evaluating the
presence of mucosal architecture loss, goblet cell depletion,
crypt abscess, cellular infiltration, and tunica muscularis thicken-
ing. The analysis has been performed in 4 to 6 animals per group.
2.9. Plasma lipopolysaccharide–binding protein by enzyme-
linked immunospecific assay
Plasma lipopolysaccharide–binding protein (LBP) concentrations
were determined using the enzyme immunoassay kit (Enzo Life
Sciences, Milan, Italy). Rat blood samples were collected in
heparinized tubes after decapitation. Samples were centrifuged
immediately at 14,000 rpm for 15 minutes, and the resulting
plasma was frozen at 280˚C until analysis. Lipopolysaccharide-
binding protein concentrations were determined using the
enzyme immunoassay kit for free mouse and rat LBP as per
manufacturers’ instruction (Enzo Life Sciences). Sensitivity: range
1 to 50 ng/mL. The analysis has been performed in 3 to 5 animals
per group.
2.10. Gene expression analysis by quantitative reverse
transcription polymerase chain reaction
Total RNA was extracted from colon samples using the mirVana
miRNA Isolation kit (Ambion/Life Technologies, Milan, Italy) accord-
ing to the manufacturer’s recommendations. RNA concentration
and quality were determined using a Nanodrop 1000 (Thermo
Scientific, Milan, Italy). Quantitative polymerase chain reaction (PCR)
was conducted in a LightCycler480 System using PowerUp SYBR
Green Master Mix (Applied Biosystems, Milan, Italy) and specific
probes designed by Applied Biosystems to rat occludin, ZO-1,
tumor necrosis factor (TNF)-a, interleukin (IL)6, IL10, and trans-
forming growth factor (TGF)-b, while using b-Actin as an
endogenous control. Experimental samples were run in triplicate
with 4 mL (10 ng·mL21) complementary DNA per reaction. To check
for amplicon contamination, each run contained no template
controls in triplicate for each probe used. Cycle threshold (Ct) values
were recorded. Data were normalised using b-Actin and trans-
formed using the 22DDCt method. No significant differences were
observed in the messenger RNA (mRNA) expression levels of
b-actin between groups. The analysis has been performed in 4 to 6
animals per group.
2.11. Statistical analysis
All the experimental procedures were performed by a researcher
blind to the treatment. Results were expressed as mean6 SEM.
The analysis of variance (ANOVA) was performed by one-way
ANOVA with Bonferroni’s significant difference procedure used
for post-hoc comparisons. P values of less than 0.05 were
considered significant. Data were analyzed using the “Origin 9”
software (OriginLab, Northampton, MA). Statistical analysis on
16S sequencing data was performed by QIIME2 using non-
parametric tests. Differences in relative abundance of bacterial
taxa were evaluated using the Kruskal–Wallis test on pairwise or
multiple comparisons. The permutational ANOVA (PERMANOVA)
test was applied to beta diversity distance matrices generated by
QIIME2 to test the significance between samples’ clusters
observed after principal coordinate analysis (PCoA); significance
was determined through 999 permutations. Spearman correla-
tion coefficients between relative abundances of microbial taxa
and levels of SCFAs were computed using GraphPad Prism 6
(GraphPad Software, La Jolla, CA).
3. Results
3.1. Faecal microbiota transplantation from
dinitrobenzenesulfonic acid donors transfers
visceral hypersensitivity
A scheme of the experimental protocol has been reported in
Figure 1A. Overtime visceral sensitivity has been assessed by both
abdominal withdrawal reflex (AWR) and viscero-motor response
(VMR) to colorectal distension (CRD). To limit the effects of the
antibiotics on visceral sensitivity, we investigated the minimum
treatment duration needed to obtain a sufficient microbiota depletion
before proceeding with FMT. The culture-based analyses performed
on freshly collected faecal pellets showednoviable bacterial cells after
7 days of treatment. The antibiotic treatment induced visceral
hypersensitivity as assessed by AWR (Fig. 1B, day 7), whereas the
VMR was unaltered (Fig. 1C, day 7). Antibiotic-induced hypersen-
sitivity wasmild on day 12 and completely disappeared on day 18, as
assessed, respectively, byAWR (Fig. 1B) and VMR (Fig. 1C). Starting
on day 7 and following the scheme reported in Figure 1A, FMT was
performed using faeces from control (FMTCTR) or from animals in
which a severe visceral painwas inducedby the intrarectal injection of
DNBS (FMTDNBS).
FMTDNBS induced, in comparison with FMTCTR, a significant
increase of both AWR and VMR to CRD after the set I of FMT
(respectively, Figs. 1B and C, days 12-18). Hypersensitivity was
consolidated after the set II of FMT (Figs. 1D and E, days 26-32), in
particular when evaluated as AWR in awake animals (day 39; Fig.
1D). Three weeks after the interruption of treatments, the effect of
FMTDNBS ended, indeed the visceral sensitivity of abx 1 FMTDNBS
animals appearednot different from that registered in controls onday
46 (Figs. 1D and E). FMTCTR did not induce significant effects on
pain threshold, showing nodifferences in comparisonwith the group
abx1 vehicle at each time tested.
We observed similar results in preliminary experiments using a
longer antibiotic treatment (24 days), although the effect of
microbiota transplantation on visceral sensitivity was less clear
because of the persistence of antibiotic-induced gut sensitivity
alterations (Figure S1, available as supplemental digital content at
http://links.lww.com/PAIN/B462).
3.2. Visceral hypersensitivity is accompanied by alteration of
the gut microbiota composition
The taxonomic analysis of faecal suspensions, subsequently used
for FMT, revealed several differences between control and DNBS-
treated animals (Figure S3A, available as supplemental digital
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Figure 1. Effect of antibiotic treatment and FMT from DNBS-treated animals on visceral sensitivity of naive recipients. As shown in the scheme (A), rats were
treated, with a combination of antibiotics for 7 days; the control group was treated with vehicle. On day 7, the abx-treated animals were divided into 3 groups, FMT
from CTR donors, FMT from DNBS donors or vehicle, and were, respectively, administered per os for 5 consecutive days. One week after, the administrations
were repeated. Behavioural tests were performed at the end of the antibiotic treatment, 24 hours and 7 days after each cycle of FMT and once week after the last
treatment. Visceral sensitivity was assessed in the animals by measuring the AWR (B,D) and the VMR (C,E) to CRD (0.5-3 mL). Each value is the mean6 SEM of 5
rats per group in the VMR test and 10 or 14 (abx 1 FMTDNBS) rats per group for the AWR test. Statistical analysis was one-way analysis of variance followed by
Bonferroni post hoc comparison. *P, 0.05 and **P, 0.01 vs vehicle or vehicle1 vehicle–treated animals. §P, 0.05 and §§P, 0.01 vs abx1 FMTCTR–treated
animals. abx, antibiotics; AWR, abdominal withdrawal reflex; CRD, colorectal distension; CTR, control animals; DNBS, dinitrobenzenesulfonic acid; FMT, faecal
microbiota transplantation; VMR, visceromotor response.
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content at http://links.lww.com/PAIN/B462). For instance, the
phylumVerrucomicrobia showed a diminishing trend in suspensions
from DNBS-treated animals, and at lower taxonomic level, the
Prevotellaceae family was almost absent in the same suspensions,
whereas other families were found to be underrepresented,
including Akkermansiaceae and Lactobacillaceae; on the other
hand, an expansion of the Bacteroidaceae and Tannerellaceae
families was identified (Figure S3A, available as supplemental digital
content at http://links.lww.com/PAIN/B462).
Analysis of the alpha diversity in samples collected after the I and II
set of FMT (day 18 and 46) showed a significantly greater microbial
diversity in samples from the groups of animals receiving abx 1
FMTCTR and abx 1 FMTDNBS compared with others (vehicle 1
vehicle and abx 1 vehicle; Figure S3B, available as supplemental
digital content at http://links.lww.com/PAIN/B462). This observation
suggested a stable engraftment of gut microbiota after trans-
plantation, whereas an antibiotic-driven dysbiosis was still persisting
in animals of the abx 1 vehicle group. Such differences were even
more marked on day 46, where the II set of FMT was clearly
associated with a higher microbial diversity in samples from abx 1
FMTCTR and abx 1 FMTDNBS compared with controls. The long-
lasting effect of the antibiotic and antifungal treatmentwas still evident
in samples from animals belonging to the abx 1 vehicle group that
displayed an overall lower microbial richness compared with other
groups (Figure S3B, available as supplemental digital content at
http://links.lww.com/PAIN/B462). On day 32, samples from the abx
1FMTDNBS groupwere characterized by amicrobial richness slightly
higher, although not significant, than samples from abx1 FMTCTR.
Evaluation of beta diversity through PCoA using the Bray–Curtis
metric showed that samples from the abx1 vehicle group clustered
away from samples of corresponding controls (ie, controls at day 18
and 46), suggesting a different composition of the gut microbiota
(Fig. 2A). Defined clusters of samples belonging to the abx 1
FMTCTR and abx 1 FMTDNBS groups were identifiable on PCoA
plots on day 18 (PERMANOVA,P5 0.03; test statistic, 4.49), day 32
(PERMANOVA, P 5 0.04; test statistic, 5.70), and day 46
(PERMANOVA, P 5 0.02; test statistic, 3.54), with a more
pronounced group separation occurring on day 32 (Fig. 2B).
Analysis of beta diversity using the weighted UniFrac metric, which
also considers the taxa phylogenetic relatedness in addition to their
abundances, revealed a clustering behaviour similar to that pre-
viously observed for the abx1 FMTCTR and abx1 FMTDNBS groups
(ie, using the Bray–Curtis metric) (Figs. S4A and B, available as
supplemental digital content at http://links.lww.com/PAIN/B462).
Samples from fecal suspensions obtained from control
(FMTCTR) or DNBS-treated (FMTDNBS) animals were found to
cluster away from each other (PERMANOVA, P 5 0.02; test
statistic, 3.81), consistently with their different source; moreover,
when grouped by the I or II set of FMT, FMTCTR and FMTDNBS
samples clustered away also from their corresponding recipients,
although not significantly (Fig. S4B, available as supplemental
digital content at http://links.lww.com/PAIN/B462).
Consistently with the sample clustering observed on beta diversity
PCoA plots, analysis of the taxonomic composition of samples
belonging to the abx1 FMTCTR and abx1 FMTDNBS groups pointed
out to several significant differences at the phylum and family level. In
detail, although no major changes in the relative abundance of most
represented phyla were detected at day 18, an expansion of the
Lactobacillaceae and Staphylococcaceae families was observed in
samples from the abx 1 FMTDNBS and from the abx 1 FMTCTR
groups (Kruskal–Wallis P, 0.043), respectively (Figs. 2C and D). At
day 32, marked changes were identified in samples from the abx 1
FMTDNBS at a phylum level, showing a higher Firmicutes to
Bacteroidetes ratio and a contraction of Proteobacteria and
Actinobacteria (Kruskal–Wallis P5 0.02); at the family level, the most
noticeable changeconsisted in a large expansion of Lachnospiraceae
and a concomitant contraction of Enterobacteriaceae and Burkhol-
deriaceae in samples from the abx 1 FMTDNBS (Kruskal–Wallis P 5
0.02). Additional statistically significant variations (Kruskal–Wallis P,
0.047) have been observed in samples from the abx1FMTDNBS and
from the abx 1 FMTCTR groups at day 32, although occurring at a
lower extent (Figs. 2C and D). At day 46, some of the previously
observed signatures were still present in samples from the abx 1
FMTDNBS group, as the higher Firmicutes to Bacteroidetes ratio, an
even more pronounced expansion of the Lachnospiraceae family,
and a contraction of Enterobacteriaceae and Burkholderiaceae
relative abundances (Kruskal–Wallis P , 0.043) (Figs. 2C and D).
Interestingly, a peculiar variation trend was observed in the relative
abundance of Akkermansiaceae, being overall equally represented in
samples from the abx1 FMTCTR and abx1 FMTDNBS groups at day
18 and 46 and almost disappeared in samples from the abx 1
FMTDNBS group at day 32 (Fig. 2D). Furthermore, a grouped analysis
of the taxonomic profiles of FMTCTR and abx1FMTCTR samples after
the I and II set of FMT, as well as of FMTDNBS and abx 1 FMTDNBS,
was performed. Results showed that a close match between the
transplanted fecal material and recipient animals was not detectable
after both sets of FMT (Fig. S5, available as supplemental digital
content at http://links.lww.com/PAIN/B462), thus corroborating the
results obtained by the beta diversity analysis on these samples.
3.3. Changes in the levels of faecal short-chain fatty acids are
associated with visceral hypersensitivity
Faecal pellets were collected from animals undergoing to FMTs 7
days after the I and the II set of treatment (days 18 and 32) and 3
weeks after the last treatment (day 46). An increase of the total
amount of SCFAswas found in the abx1FMTDNBS group in respect
to the abx1 FMTCTR. This difference was detectable already on day
18, becoming significant on day 32 and extinguished on day 46 (Fig.
3A). Further in-depth analysis revealed that alteration onday 18were
because of an overall increase of fatty acids, whereas on day 32,
acetic acid alone was found to be raised, whereas butyric acid
significantly decreased (Figs. 3B–D).
Correlation analyses between the concentration of SCFAs and
relative abundances of microbial taxa that were previously found to
statistically differ in abx 1 FMTCTR and abx 1 FMTDNBS groups
revealed that some time-dependant associations were identifiable.
In detail, after the I set of FMT at day 18, Peptococcaceae and
Clostridiales vadin BB60 group were found to be negatively
correlated with butyric acid (Spearman r range: 20.857, 20.821;
P , 0.035), whereas the Lactobacillaceae family was positively
correlatedwith acetic acid (Spearman r:10.850,P: 0.02). After the II
set of FMT at day 32, several bacterial families were found to be
negatively correlatedwith acetic acid (Spearman r range:20.778,2
0.881;P, 0.030), includingBurkholderiaceae, Enterobacteriaceae,
Bifidobacteriaceae, Enterococcaceae, andMollicutes RF39, as well
as 2 phyla including Actinobacteria and Proteobacteria (Spearman r
range:20.928,20.833;P, 0.015). On day 46,Rikkenellaceae and
Anaeroplasmataceae were positively correlated with isobutyric acid
(Spearman r range: 0.898, 0.803; P , 0.025) (Fig. S6, available as
supplemental digital content at http://links.lww.com/PAIN/B462).
3.4. Faecal microbiota transplantation including the source
does not affect colon histology
Colon samples were collected on days 7 (24 hours after the end of
antibiotic treatment), 32 (when the effect of FMT on pain was well
established) and 46 (when the effect of FMT extinguished). The
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macroscopic damage score highlights the presence of hyperaemia
and a slight thickening of wall after the antibiotic treatment
(day 7; Fig. 4A left panel). These results were confirmed by
microscopic analysis: An infiltration of neutrophils in mucosa
and submucosa was revealed in the animals receiving the
antibiotic treatment (day 7; black arrow; Fig. 4A right panel).
Figure 2. Analysis of beta diversity and taxonomic profiles. Principal coordinate analysis plots based on the Bray–Curtis beta diversity metric showing (A) the
clustering pattern (left) among samples from CTR and from antibiotic-treated animals after vehicle administration (abx1 vehicle); (B) the clustering pattern (right)
among samples from antibiotic-treated animals subjected to FMT from controls (abx 1 FMTCTR) or from DNBS-treated animals (abx 1 FMTDNBS). Samples
obtained from control (FMTCTR) or DNBS-treated (FMTDNBS) animals and used for the I and II set of FMT are also shown. The percentage of total variance explained
is shown for each component. Taxonomic composition at the phylum (C) and family (D) level of samples belonging to the abx1 FMTCTR and to the abx1 FMTDNBS
group; microbial taxa showing a statistically significant difference (Kruskal–Wallis P, 0.05) in their relative abundance between groups are marked with a star (*) in
each legend box. abx, antibiotics; CTR, control animals; DNBS, dinitrobenzenesulfonic acid; FMT, faecal microbiota transplantation.
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The tissue alteration disappeared after the interruption of
antibiotic treatment. No macroscopic or microscopic differ-
ences were observed in the animals receiving FMTs (day 32
and 46; Figs. 4B and C, respectively).
3.5. Faecal microbiota transplantation does not affect gut
permeability factors
Gutpermeabilitywas indirectlyevaluatedbyassessing theplasma levels
of LBP (Fig. 5A) and also by measuring the mRNA expression of the
Figure 3. Effect of FMT on faecal SCFAs concentrations. HPLC analysis of (A) total SCFAs, (B) acetic acid, (C) propionic acid, (D) butyric acid, and (E) other fatty acids
concentration in faecal pellets. Each value represents themean6SEMof 9 (day18) or 5 (day 32and46) animals per group. Statistical analysiswas one-way analysis of
variance followed by Bonferroni post hoc comparison. **P , 0.01 and *P , 0.05 vs abx 1 FMTCTR treated animals. abx, antibiotics; CTR, control animals; DNBS,
dinitrobenzenesulfonic acid; FMT, faecal microbiota transplantation; SCFA, short-chain fatty acid.
8 E. Lucarini et al.·00 (2021) 1–17 PAIN®
tight junctions occludin and Zo-1 in the colon (Figs. 5B and C,
respectively).
No significant alteration in the plasma levels of LBP was found
among the experimental groups; a trend towards increase was
observed after the antibiotic treatment (Fig. 5A; day 7).
Real time polymerase chain reaction analysis of colon tight
junctions revealed amarginal increase (not statistically significant)
of occludin mRNA after the antibiotic treatment (day 7; Fig. 5B).
On the contrary, on day 7, after the antibiotic regime, Zo-1mRNA
significantly increased (Fig. 5C). Neither occludin nor Zo-1 was
affected by FMTs (Figs. 5B and C, respectively).
3.6. Faecal microbiota transplantation alters gut cytokines
profile, irrespective of the donor
The expression of TNF-a, IL-6, IL-10, and TGF-bmRNA levels was
measured in the colon by real time PCR. The antibiotic regimen
causeda long-lasting upregulation of both proinflammatory andanti-
inflammatory cytokines expression (day 7; Fig. 6). This deregulatory
effect of antibiotics was not fixed by FMT (day 32; Fig. 6).
On the other hand, the cytokines profile of the FMT recipients
did not match the pattern observed in the donors. The expression
of the analyzed cytokines (TNF-alpha, IL-6, IL-10, and TGF-b)
resulted augmented in DNBS donors in respect to CTR donors
(Figs. 6A–D) although only the increase of IL-6 and TGF-b
resulted significant (Figs. 6BandD). Despite this, either FMTDNBS
or FMTCTR recipient animals showed an overexpression of IL-6
and TGF-b (day 32, Figs. 6B and D, respectively). At the same
time, TNF-alpha and IL-10 were respectively upregulated in
FMTCTR and FMTDNBS recipients (day 32; Figs. 6A and B,
respectively). On day 46, all cytokines were still upregulated in the
abx1 vehicle group and in the abx1 FMTCTR group. By contrast,
in the abx 1 FMTDNBS, all cytokines, with exception of TGF-b
(Fig. 6D), returned to the values observed in controls
(Figs. 6A–C).
3.7. Transfer ofmicrobiota fromhealthy controls counteracts
postinflammatory visceral pain persistence
Finally, we tested the hypothesis that visceral pain could be
suppressed or reduced by FMT from healthy donors. Pain threshold
was assessed by evaluating the animal AWR in response to CRD
stimulus at different timepoints after DNBS injection and FMT (Fig.
7A). As expected, 7 days after the induction of the damage, the
abdominal withdrawal response to CRD was significantly higher in
both the groups treatedwith DNBS (Fig. 7B, day 7). The FMTCTR led
to a progressive reduction of visceral hypersensitivity in DNBS-
treated animals that became significantly lower after the third
transplant cycle (Fig. 7C, day 28) and consolidated after the fourth
one (Fig. 7C, day 35). As a result of FMT, DNBS animals displayed a
visceral sensitivity significantly lowered up to 17 days after the
treatment interruption (Fig. 7D, day 49). On day 56 (Fig. 7D), the
behavioural response of these animals to CRD resulted not
significantly reduced compared with DNBS 1 vehicle–treated
animals, and no differences were observed between DNBS animals
receiving vehicle or FMT on day 63 (Fig. 7D).
4. Discussion
The present work highlights the relevance of microbiota in pain
signalling from the gut. The FMT from animals affected by visceral
pain to healthy rats was sufficient to induce visceral hypersen-
sitivity. On the other hand, the manipulation of gut microbiota by
FMT induced a reduction of persistent visceral pain in DNBS
animals. A strong association between animals’ pain threshold
and microbiota composition changes was demonstrated.
Although the gut microbiota seemed to be clearly involved in
visceral pain regulation,32,47,70 the evidence collected so far are
circumstantial.24,42,90 Moreover, little is known on the evolution of
microbiota over time after transplantation from animals affected
by a disease, like pain, to naive recipients. The only other
evidence about the involvement of microbiota perturbations in
visceral pain was obtained in another model of colitis induced by
DSS.30 We report the active involvement of microbiota alterations
in the persistence of pain after colitis resolution in the animal
model induced by DNBS,which differs from theDSSmodel either
for the aetiology, for the localization of the damage, and for the
course of the disease, providing different insight into clinical
translatability.3,37,38,53,92 Furthermore, the present work demon-
strates significant temporal correlations between the composition
of bacteria, their products (SCFAs), and pain in the animals
receiving FMT rather than in the donors, which represents an
original aspect compared with the previous findings. Yet, for the
first time, it has been demonstrated that the effect of FMT is long
lasting but reversible and that the final balance is strongly affected
by the environment where the microbiota is transplanted.
As suggested by the analysis of the beta diversity in samples
from FMTDNBS animals, major modifications in the composition
and structure of the gut microbiota occurred after the FMT set II
(day 32), correlating with a significantly increased response of
these animals to CRD. At a later stage (day 46), when the
difference in visceral sensitivity perception disappeared, a less
pronounced variation in beta diversity was observed.
Evaluation of taxonomic profiles confirmed that marked differ-
ences between the animals that underwent the FMTCTR or FMTDNBS
were identifiable on day 32 at the phylum and family level for major
members of gut microbiota, including protective microbial taxa
known to be associated with gastrointestinal health (ie, Akkerman-
siaceae).17,61Akkermansiamuciniphila is known tomediate a variety
of host functions ranging from metabolism to immune regula-
tion.27,28,73 Regarding its role in pain syndromes or functional
gastrointestinal disorders, A. muciniphila was found to be signif-
icantly reduced in children with IBS78 as well as in animal models of
postinflammatory IBS.20 Recently, Guida et al.40 reported that pain
related todysbiosis in vitaminDdeficientmicewasamelioratedbyan
anandamide congener, in concomitance with increased levels of
Akkermansia, Eubacterium, and Enterobacteriaceae. However,
there is little evidence for a pain-alleviating effect mediated by A.
muciniphila. One hypothesis is that SCFAs, like propionate and
acetate, both endproducts of mucus degradation by Akkermansia,
may modulate visceral nociception, as stimulation of the SCFA
receptor GPR43 has been shown to decrease visceral pain
sensitivity in healthy humans.25,85 The SCFAs have been associated
to human gastrointestinal disorders68 and proposed as regulators of
visceral sensitivity; since the activation of their receptors, FFAR2/3
regulates leucocyte functions, such as the production of cytokines
(eg, TNF-a, IL-2, IL-6, and IL-10), eicosanoids and chemokines (eg,
CCL2).88 Nevertheless, the role of SCFAs in visceral and somatic
pain perception is still the subject of debate: depending on the
context, the effect of SCFAs signalling can be either analgesic or
nociceptive.50 Clinical evidence has shown that butyrate, a SCFA
found dramatically reduced in the faecal samples of IBS and IBD
patients, is highly effective in relieving abdominal pain.4,46 The
significant reduction of butyrate in the FMTDNBS group onday 32 is in
line with this evidence. Nevertheless, despite the reduction of
butyrate on day 32, the total amount of SCFAs increased in these
animals both on day 18 and 32 mainly contributed by an
overproduction of acetate. Specific bacterial taxa were found to be
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negatively correlated with the increased acetate levels uniquely on
day 32, suggesting the presence of a defined microbiota profile at
this stage. Of note, the recently identified bacterial genus
Acetatifactor belonging to Lachnospiraceae, one of the most
prominent bacterial family being expanded in samples from the
FMTDNBS group, and showing strong acetate-producing capabil-
ities,76 resulted overrepresented in FMTDNBS samples (Fig. S4C,
available as supplemental digital content at http://links.lww.com/
PAIN/B462). However, there are no consistent data in literature
reporting a negative impact of acetate on gut physiology. Short-
Figure 4. Histological evaluation of colon damage after the antibiotic regimen and the FMT. Macroscopic damage score (left panel) and representative
microphotograph of haematoxylin or eosin-stained colon slices. Each value represents themean6SEMof 6 (A - day 7 and B - day 32) or 4 (C - day 46) animals per
group. Statistical analysis was one-way analysis of variance followed by Bonferroni post hoc comparison. **P, 0.01 vs vehicle-treated animals. abx, antibiotics;
CTR, control animals; DNBS, dinitrobenzenesulfonic acid; FMT, faecal microbiota transplantation.
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chain fatty acids modulate immune and inflammatory responses
through activation of free fatty acid (FFA) receptors type 2 and 3
(FFA2 and FFA3 receptors) and G protein–coupled receptor 109A
(GPR109A, known as hydroxyl-carboxylic acid 2, HCAR2) and
inhibition of histone deacetylases.56 Recently, HCAR2 was found to
regulate neuroinflammation and nervous system plasticity in
neuropathic pain10 and multiple sclerosis.18,72 HCAR2 has been
found to express in the hypothalamus, a vital integration site during
ascending pain transduction.57 Despite all these evidences that
suggest the potential mechanistic benefits of SCFA receptors in
inflammation and pain transduction, studies directly investigating the
role of SCFA receptors in visceral pain are still lacking. Bymonitoring
the time course modifications and evolution of the gut microbiota in
this model, emerged that the effects of FMT were long lasting but
temporary, demonstrating thepresenceof a continuousbidirectional
influence between the microbiota and the gut, as previously
postulated.23,44 FMTDNBS-induced visceral hypersensitivity was
evident already 24 hours after the first set of FMT, suggesting the
presence of pain mediators in the supernatant obtained from the
faeces, as supposed in other studies.13,90 The presence of residual
DNBS in the solutions used for the FMT has been excluded by High
Performance Liquid Chromatography (HPLC) analysis (Fig. S2,
available as supplemental digital content at http://links.lww.com/
PAIN/B462). Besides, the presence of pain mediators in the faecal
medium cannot be excluded and might explain the acute effect of
FMT. By contrast, the long-lasting hyperalgesia observed in these
animals is not attributable to the acute stimulation, nor to local
intestinal irritation, because colon histological analysis revealed no
damage on day 32 (7 days after the last FMT). Although these
findings support the idea of an active role of microbiota in pain
induction by FMT, it remains to be clarifiedwhich factor(s) among the
microbiota itself or its metabolic output or some host-derived
metabolites contributed the most to this phenomenon. Besides, the
apparent longer persistence of visceral hypersensitivity in the AWR
test in respect to the VMR test suggested a possible central
sensitization to the painful stimulus induced by CRD. Similarly, in the
animals treated with DNBS, VMR was significantly decreased after
4 weeks, whereas the augmented AWR persisted up to 13 weeks
after DNBS injection.59
A slight increase in gut permeability occurred after the antibiotic
treatment, with an increase in the expression of Zo-1, which has
been positively correlated with a leaky gut.31 This finding is
Figure 5.Effect of antibiotic regimenandFMTongut permeability. (A) Elisa assay for LBP in plasmasamples. Analysis of occludin (B) andZo-1(C) geneexpression oncolon
samples byRT-quantitativePCR.ThemRNAexpressionwasnormalized tob-actin, and fold changeswere expressed in comparisonwith the control group. (A) Each value
is themean6SEMof 3 or 5 (vehicle1 vehicle group) animals per group; (B andC) Each value is themean6SEMof 6 (donors, day 7 and day 32) or 4 (day 46) animals per
group. Statistical analysis was one-way analysis of variance followed by Bonferroni post hoc comparison. *P , 0.05 and **P , 0.01 vs vehicle-treated animals. abx,
antibiotics; CTR, control animals; DNBS, dinitrobenzenesulfonic acid; FMT, faecal microbiota transplantation LBP, lipopolysaccharide-binding protein; mRNA,messenger
RNA.
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consistent with the previously demonstrated positive effect of
microbiota on gut barrier integrity maintenance.82
The bacterial community participates in maintaining intestinal
homeostasis through the “training” of the immune system and
inhibiting the growth of pathogens.49 The analysis of gene
expression in the gut confirmed a derangement of cytokines as a
result of both the antibiotic treatment and the FMT, but no
significant correlations were found between the cytokines profiles
among the groups and the observed differences in visceral pain.
Moreover, the cytokine levels of recipients did not reflect those of
the respective DNBS and CTR donors. On day 32, FMTCTR
recipients showed increased levels of TNF-a, IL-6, and TGF-b,
although their pain threshold was unaltered. At the same time, in
FMTDNBS recipients, visceral hypersensitivity was associated to
Figure 6. Effect of antibiotic regimen and FMT on the gut cytokines profile. Analysis of TNF-a (A), IL-6 (B), IL-10 (C), and TGF-b (D) gene expression on colon
samples by Real Time PCR. ThemRNA expression was normalized to b-actin, and fold changeswere expressed in comparison with the control group. Each value
is the mean6 SEM of 6 (donors, day 7 and day 32) or 4 (day 46) animals per group. Statistical analysis was one-way analysis of variance followed by Bonferroni
post hoc comparison. *P, 0.05 and **P, 0.01 vs vehicle-treated animals. abx, antibiotics; CTR, control animals; DNBS, dinitrobenzenesulfonic acid; FMT, faecal
microbiota transplantation; IL, interleukin; mRNA, messenger RNA; TGF, transforming growth factor; TNF, tumor necrosis factor.
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Figure 7. Therapeutic effect of FMT on DNBS-induced postinflammatory visceral pain. As shown in the scheme (A), rats were intrarectally injected with DNBS (30
mg in 0.25 mL EtOH 50%); on day 7, DNBS-injected animals were divided into 2 groups, respectively, administered with the vehicle or the FMT from CTR donors
per os for 5 consecutive days. The FMT set was weekly repeated for 4 times. Behavioral tests were performed at the end of the antibiotic treatment, 3 days after
each cycle of FMT, and once aweek afterwards (B-D). Visceral sensitivity was assessed in the animals bymeasuring the AWR to CRD (0.5-3mL). Each value is the
mean6 SEM of 5 animals per group. Statistical analysis was one-way analysis of variance followed by Bonferroni post hoc comparison. *P, 0.05 and **P, 0.01
vs vehicle or vehicle 1 vehicle–treated animals. ^P , 0.05 and ^^P , 0.01 vs DNBS 1 vehicle–treated animals. abx, antibiotics; AWR, abdominal withdrawal
reflex; CRD, colorectal distension; CTR, control animals; DNBS, dinitrobenzenesulfonic acid; FMT, faecal microbiota transplantation.
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increased levels of IL-10, IL-6, and TGF-b. With respect of
FMTCTR, animals receiving FMTDNBS displayed increased levels of
IL-10 and a decreased level of TNF-a, despite these differences
were not statistically significant. A number of evidence in the
literature attests TNF-a contributes to enhance pain,36 whereas
IL-10 is mostly reported to counteract the development of
pain.55,84 In the gut, both T cells and M2 macrophages can
release IL-10 and opioid peptides that can signal to sensitized
pain-sensing neurons in the peripheral and central nervous
system to reverse or control sensitization and resolve pain.51
Nevertheless, colitis in IL-102/2 mice was not found to be
associated with abdominal pain.7 Clinically, the TNFa serum level
was significantly higher, and IL-10 was significantly lower in IBS
patients compared with healthy controls.21 Yet, mucosal mRNA
expression of IL-10 tended to be decreased in IBS patients
affected by visceral hypersensitivity.8
Then, we analysed the effect of FMT on tryptophan metabolism
(Tables S1 and 2, available as supplemental digital content at http://
links.lww.com/PAIN/B462), considering it is differentially affected in
intestinal diseasescharacterizedbypersistent pain, like IBSand IBDs,
and it is directly or indirectly controlled by themicrobiota.1 In addition,
we measured monoamine in the gut because of their impact on the
microbiota–gut–brain axis physiology80 and their critical role in the
modulation of pain.5,6,12 A decrease in plasma tryptophanwas found
in DNBS donors, likely consequent to an increased biosynthesis of
serotonin in the gut, as confirmed by the HPLC (Tables S3 and 4,
available as supplemental digital content at http://links.lww.com/
PAIN/B462). This phenomenon, which is a characteristic conse-
quence of intestinal damages, can directly influence the neuronal
firing of visceral afferents.64,69 A plasma tryptophan decrease was
also detected in the animals that underwent FMT and correlated to a
massive and long-lasting increase of serotonin in the faeces (Table
S6, available as supplemental digital content at http://links.lww.com/
PAIN/B462), but not in the gut tissue (Table S3, available as
supplemental digital content at http://links.lww.com/PAIN/B462). An
increase of 5-HT in the gut lumen has been recently demonstrated to
selectively modulate the colonization of bacteria species in the gut.35
Nevertheless, nodifferencewas foundbetween the animals receiving
the FMT from CTR or from DNBS donors, demonstrating again that
5-HT is not involved in the transfer of pain mediated by FMTDNBS.
The decrease of dopamine consequent to the antibiotic
treatment and the FMT (Tables S5 and 7, available as
supplemental digital content at http://links.lww.com/PAIN/
B462) resulted in line to previous data reporting an antibiotic-
mediated reduction of this neurotransmitter in the gut, where it
plays a role in gastrointestinal motility regulation.58 In accordance,
the clearance of gut microbiota by antibiotic cocktail reduced the
synthesis of dopamine in intestines and exacerbated liver
damage, and the alteration in dopamine levels was restored by
the recovery of gut microbiota.83,94 Physiological studies suggest
that dopaminergic mechanisms are important in the regulation of
gastrointestinal motility,87,89 directly or after its metabolism to
noradrenaline.48,63,67 The gut levels of dopamine were reduced
also in DNBS donors, which reported alterations in the
gastrointestinal motility.2 Further study needs to evaluate the
impact of dopamine reduction in the gut of animals receiving the
FMT. The antihyperalgesic effect obtained after manipulation of
the gut microbiota in DNBS animals contributes further to sustain
the role of microbiota in pain signalling. Currently, many
discrepancies do exist on the therapeutic potential of FMT.93
So far, it has been considered a good protocol to maintain a low
number of FMT and supplied by a single donor.16,91 However,
recent clinical studies highlighted the efficacy of a multiple donor
and repeated treatment-based therapy in patients affected by
ulcerative colitis, chronic intestinal pseudo-obstruction, and
IBS.29,39,74 In certain pathological conditions, the interactions
between genetic, immunological, and environmental factors
might determine a state more resistant to therapeutic microbial
manipulation.79 In the preclinical model of colitis-induced visceral
hypersensitivity, we obtained a substantial reduction in pain after
4 cycles of FMT, using different donors. It is likely that the
“inflammatory” environment wherein the microbiota is trans-
planted may pose as an obstacle to the engraftment of some
microbial taxa comparedwith others. In this case, the repetition of
the FMT could “force” the host to accept the newly introduced
microbial communities. These findings suggest the possibility to
enhance the therapeutic efficacy of FMT by developing different
protocols according to the specific disorder to be treated.
Moreover, the FMT outcome is drastically influenced by the
microbial diversity of the donor’s stool, so the identification of a
“super donor” profile is pivotal for therapeutic purposes.91
In conclusion, further evidence about the active contribution of
the gut microbiota to visceral pain induction and persistence has
been provided by this study, strengthening the role of FMT as a
promising therapeutic approach for abdominal pain. However,
major knowledge gaps remain. Continued efforts in improving the
mechanistic understanding of how visceral sensitivity can be
modulated by the gut microbiota are therefore warranted.
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